A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia. That’s a potential game changer for the more than 6 million Americans diagnosed each year and the 100,000 who die from the memory-robbing disease annually.

A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and similar GLP-1 agonists, but without muscles loss as a potential side-effect. This is the conclusion of a new study by an international team of researchers led from the biotech firm Atrogi AB.

Weight loss drug Wegovy, which also goes by the name Ozempic, is responsible for slimming down celebrities such as Oprah Winfrey, threatening the profits of global junk food companies and potentially decreasing obesity rates in the US.